Open Demat
Be a Partner
Samadhan
Install App
Install App

16725

532983

RPGLIFE

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

RPG LIFE SCIENCES LTD Share Price Update

As of the latest trading session, RPG LIFE SCIENCES LTD is trading at ₹2298.3, up by ₹24.10 or 1.05% from its previous close. The stock has moved between ₹2253.60 and ₹2329.00 today. Over the past year, the stock has delivered a return of 4.75%. In the last month, it has returned 13.78%.

RPG LIFE SCIENCES LTD performance

Today’s low Today’s high
₹ 2253.60 ₹ 2329.00
₹ 2293.90
52 week low 52 week high
₹ 1733.00 ₹ 2725.00
₹ 2293.90
Open Price ₹ 2274.20
Prev. Close ₹ 2274.20
Volume (Shares) 5922.00
Total traded value ₹ 135.84
Upper Circuit ₹ 2729.00
Lower Circuit ₹ 1819.40
info

Investment Returns

Over 1 Month 13.78% Over 3 Months 19.15% Over 6 Months 0.89% Over 1 Year 4.75%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

RPG LIFE SCIENCES LTD fundamentals


  • Market cap (Cr) 3,793.90
  • P/E Ratio (TTM) 32.62
  • Beta 0.73
  • Book Value / share 366.02
  • Return on equity 25.53%
  • EPS (TTM) 67.87
  • Dividend yield 1.06%
  • Net profit/quarter (Cr) 29.90
info icon alternate text
  • Market cap (Cr) 3,802.30
  • P/E Ratio (TTM) 32.62
  • Beta 0.66
  • Book Value / share 366.02
  • Return on equity 25.53%
  • EPS (TTM) 67.87
  • Dividend yield 1.06%
  • Net profit/quarter (Cr) 29.90
info icon alternate text

RPG LIFE SCIENCES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 176.89
Operating Expense 150.14
Net Profit 29.90
Net Profit Margin (%) 16.90
Earnings Per Share (EPS) 18.08
EBITDA 46.33
Effective Tax Rate (%) 25.62
Particulars DEC 2025 (Values in Cr)
Revenue 180.03
Operating Expense 145.90
Net Profit 22.13
Net Profit Margin (%) 12.29
Earnings Per Share (EPS) 13.38
EBITDA 34.75
Effective Tax Rate (%) 24.00
Particulars SEP 2025 (Values in Cr)
Revenue 181.68
Operating Expense 147.99
Net Profit 36.85
Net Profit Margin (%) 20.28
Earnings Per Share (EPS) 22.28
EBITDA 54.79
Effective Tax Rate (%) 25.48
Particulars JUN 2025 (Values in Cr)
Revenue 168.92
Operating Expense 138.72
Net Profit 26.29
Net Profit Margin (%) 15.56
Earnings Per Share (EPS) 15.90
EBITDA 40.70
Effective Tax Rate (%) 25.79
Particulars MAR 2025 (Values in Cr)
Revenue 143.09
Operating Expense 123.15
Net Profit 117.35
Net Profit Margin (%) 82.01
Earnings Per Share (EPS) 70.96
EBITDA 140.45
Effective Tax Rate (%) 13.00
Particulars MAR 2026 (Values in Cr)
Revenue 707.52
Operating Expense 582.76
Net Profit 115.17
Net Profit Margin (%) 16.27
Earnings Per Share (EPS) 69.64
EBITDA 176.56
Effective Tax Rate (%) 25.31
Particulars MAR 2025 (Values in Cr)
Revenue 653.43
Operating Expense 515.83
Net Profit 183.24
Net Profit Margin (%) 28.04
Earnings Per Share (EPS) 110.80
EBITDA 254.93
Effective Tax Rate (%) 21.31
Particulars MAR 2024 (Values in Cr)
Revenue 582.05
Operating Expense 471.42
Net Profit 87.66
Net Profit Margin (%) 15.06
Earnings Per Share (EPS) 53.01
EBITDA 135.36
Effective Tax Rate (%) 25.61
Particulars MAR 2023 (Values in Cr)
Revenue 512.81
Operating Expense 425.93
Net Profit 67.64
Net Profit Margin (%) 13.19
Earnings Per Share (EPS) 40.90
EBITDA 107.49
Effective Tax Rate (%) 26.22
Particulars MAR 2022 (Values in Cr)
Revenue 440.16
Operating Expense 369.97
Net Profit 51.48
Net Profit Margin (%) 11.69
Earnings Per Share (EPS) 31.13
EBITDA 89.35
Effective Tax Rate (%) 29.64
Particulars MAR 2025 (Values in Cr)
Book Value / Share 320.80
ROE % 25.53
ROCE % 32.28
Total Debt to Total Equity 0.00
EBITDA Margin 26.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 226.67
ROE % 25.69
ROCE % 34.25
Total Debt to Total Equity 0.00
EBITDA Margin 23.43
Particulars MAR 2023 (Values in Cr)
Book Value / Share 186.00
ROE % 24.01
ROCE % 32.15
Total Debt to Total Equity 0.00
EBITDA Margin 21.12
Particulars MAR 2022 (Values in Cr)
Book Value / Share 154.66
ROE % 21.80
ROCE % 30.57
Total Debt to Total Equity 0.01
EBITDA Margin 20.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share 130.88
ROE % 20.36
ROCE % 26.41
Total Debt to Total Equity 0.03
EBITDA Margin 18.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 139.61
Total Assets 657.81
Total Liabilities 657.81
Total Equity 530.53
Share Outstanding 1
Price to Book Ratio 7.10
Return on Assets (%) 27.85
Return on Capital (%) 34.54
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 36.47
Total Assets 512.87
Total Liabilities 512.87
Total Equity 374.85
Share Outstanding 1
Price to Book Ratio 6.75
Return on Assets (%) 17.09
Return on Capital (%) 23.39
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 57.04
Total Assets 419.35
Total Liabilities 419.35
Total Equity 307.60
Share Outstanding 1
Price to Book Ratio 3.74
Return on Assets (%) 16.12
Return on Capital (%) 21.99
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 70.26
Total Assets 344.61
Total Liabilities 344.61
Total Equity 255.77
Share Outstanding 1
Price to Book Ratio 3.62
Return on Assets (%) 14.93
Return on Capital (%) 20.1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 40.75
Total Assets 303.39
Total Liabilities 303.39
Total Equity 216.45
Share Outstanding 1
Price to Book Ratio 2.96
Return on Assets (%) 13.18
Return on Capital (%) 18.36
Particulars MAR 2025 (Values in Cr)
Net Income 232.88
Cash from Operations 130.61
Cash from Investing -41.80
Cash from Financing -27.08
Net change in Cash 8.98
Free Cash Flow 166.64
Particulars MAR 2024 (Values in Cr)
Net Income 117.84
Cash from Operations 123.67
Cash from Investing -79.15
Cash from Financing -20.31
Net change in Cash -5.10
Free Cash Flow 192.90
Particulars MAR 2023 (Values in Cr)
Net Income 91.68
Cash from Operations 116.05
Cash from Investing -105.81
Cash from Financing -17.12
Net change in Cash -32.11
Free Cash Flow 148.78
Particulars MAR 2022 (Values in Cr)
Net Income 73.17
Cash from Operations 83.60
Cash from Investing -34.66
Cash from Financing -13.51
Net change in Cash 16.58
Free Cash Flow 107.55
Particulars MAR 2021 (Values in Cr)
Net Income 53.58
Cash from Operations 66.60
Cash from Investing -7.96
Cash from Financing -10.49
Net change in Cash 39.82
Free Cash Flow 75.11
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.66 14.14 1.69 250.28 23.12 40.00
BLISS GVS PHARMA LTD 294.95 23.86 2.61 3120.25 118.35 301.20
CIPLA LTD. 1401.65 27.76 3.28 113225.36 1165.55 1672.20
FERMENTA BIOTECH LIMITED 303.60 10.10 2.28 893.52 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.66 31.40 4.55 250.28 23.12 40.00
AMRUTANJAN HEALTH CARE LTD. 547.40 24.54 4.27 1582.57 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8578.15 103.09 26.84 21445.38 7630.00 10653.05
BLISS GVS PHARMA LTD 294.95 31.72 2.70 3120.25 118.35 301.20

RPG LIFE SCIENCES LTD shareholding pattern

Holding
18.72%
72.95%
0.87%
7.44%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

RPG LIFE SCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2293.90 0.86 redarrow
red-green-graph indicator
5 Bearish
11 Bullish
  • 5 Days 2295.90
  • 26 Days 2216.00
  • 10 Days 2300.50
  • 50 Days 2135.00
  • 12 Days 2294.10
  • 100 Days 2117.00
  • 20 Days 2249.80
  • 200 Days 2153.60
2291.67 PIVOT
First Support 2252.43 First Resistance 2313.43 Second Support 2230.67 Second Resistance 2352.67 Third Support 2191.43 Third Resistance 2374.43
RSI 55.32 ADX 61.51 MACD 78.06 Williams % R -90.90 Commodity Channel Index (CCI) 11.78
Date 2026-05-21 Week 3023.00 Same Day 1939.00 Month 10127.00
1 Year 0.74 3 Year 0.77
Over 1 Month
13.78% down
Over 1 Year
4.75% down
Over 3 Months
19.15% down
Over 3 Years
43.03% down
Over 6 Months
0.89% down
Over 5 Years
38.23% down

RPG LIFE SCIENCES LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
27 Jun 2025 4.0 Special 27 Jun 2025 Equity shares
27 Jun 2025 20.0 Final 27 Jun 2025 Equity shares
28 Jun 2024 16.0 Final 28 Jun 2024 Equity shares
21 Jul 2023 12.0 Final 21 Jul 2023 Equity shares
14 Jul 2022 9.6 Final 15 Jul 2022 Equity shares
13 Aug 2021 7.2 Final 17 Aug 2021 Equity shares
24 Mar 2020 4.0 Interim 26 Mar 2020 Equity shares
22 Jul 2019 2.4 Final 24 Jul 2019 Equity shares
19 Jul 2018 2.4 Final 21 Jul 2018 Equity shares
13 Jul 2017 2.8 Final 17 Jul 2017 Equity shares
22 Mar 2016 1.6 Interim 24 Mar 2016 Equity shares
20 Jul 2015 0.8 Final 22 Jul 2015 Equity shares
11 Sep 2014 0.8 Special 15 Sep 2014 Equity shares
11 Sep 2014 1.2 Final 15 Sep 2014 Equity shares
11 Jul 2013 1.2 Final 15 Jul 2013 Equity shares
24 Jul 2012 0.8 Final 26 Jul 2012 Equity shares
14 Jul 2011 1.6 Final 18 Jul 2011 Equity shares
15 Jul 2010 1.44 Final 19 Jul 2010 Equity shares
30 Jul 2009 1.2 Final 01 Aug 2009 Equity shares
11 Aug 2008 1.2 Final 13 Aug 2008 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
27 Jun 2025 4.0 Special 27 Jun 2025 Equity shares
27 Jun 2025 20.0 Final 27 Jun 2025 Equity shares
28 Jun 2024 16.0 Final 28 Jun 2024 Equity shares
21 Jul 2023 12.0 Final 21 Jul 2023 Equity shares
14 Jul 2022 9.6 Final 15 Jul 2022 Equity shares
13 Aug 2021 7.2 Final 17 Aug 2021 Equity shares
24 Mar 2020 4.0 Interim 26 Mar 2020 Equity shares
22 Jul 2019 2.4 Final 24 Jul 2019 Equity shares
19 Jul 2018 2.4 Final 21 Jul 2018 Equity shares
13 Jul 2017 2.8 Final 17 Jul 2017 Equity shares
22 Mar 2016 1.6 Interim 24 Mar 2016 Equity shares
20 Jul 2015 0.8 Final 22 Jul 2015 Equity shares
11 Sep 2014 0.8 Special 15 Sep 2014 Equity shares
11 Sep 2014 1.2 Final 15 Sep 2014 Equity shares
11 Jul 2013 1.2 Final 15 Jul 2013 Equity shares
24 Jul 2012 0.8 Final 26 Jul 2012 Equity shares
14 Jul 2011 1.6 Final 18 Jul 2011 Equity shares
15 Jul 2010 1.44 Final 19 Jul 2010 Equity shares
30 Jul 2009 1.2 Final 01 Aug 2009 Equity shares
11 Aug 2008 1.2 Final 13 Aug 2008 Equity shares

Top Gainers

up-arrow (%)

Top Losers

up-arrow (%)

RPG LIFE SCIENCES LTD Share Price

RPG Life Sciences Limited, formerly known as Searle India Limited, started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to RPG Group. The Company is engaged in manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

RPG Life Sciences Limited was incorporated on March 29, 2007 with the name 'RPG Pharmaceuticals Limited' . During the year 2007-08, as per the Scheme of Arrangement, the Company acquired the Pharmaceuticals Business of Brabourne Enterprises Limited along with all assets and liabilities pertaining to that business with effect from April 2, 2007. On February 13, 2008, the name of the Company was changed to RPG Life Sciences Limited.

During the year 2008-09, the company increased the production capacity of Bulk Drugs and Chemicals from 62 tonnes to 71 tonnes. They launched an oncology drug namely Exemestane. Also, they launched new products, namely Nufex Beta, Qugyl-O & Immunotec. In June 10, 2008, the equity shares of the company were listed on BSE and NSE with effect from June 10, 2008. In July 2008, the company commenced production in the new high capacity fermenters.

During the year 2009-10, the company strengthened their product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. The new products launched during the year were Demator, Sizomax, Mela, Exinia and Mofetyl S. They launched a new immunosuppressant product, Sirolimus, during the year. Also, they introduced 11 new products across several therapeutic segments.

The company plans to launch six new bulk drugs and two existing products in new markets. They also plan to file DMFs for several products in regulated and semi regulated markets. The company is having plans to set up dedicated divisions with their own sales force and portfolio of brands that will drive the business in therapeutic areas like oncology, psychiatry and diabetology.

New products launched were Demator, Sizomax, Mela, Exinia and Mofetyl S during the year 2009-10. The Company strengthened its product portfolio by launching new products in the antibiotic, cardiovascular, anti-ulcerant, anti-depressant, immunosuppressant and Nephrology segments. It launched a new immunosuppressant product, Sirolimus in 2010.

New divisions were launched in highly growing chronic segments namely Cardiology and Diabetic (IMPULSE), NeurologyPsychiatry (EMPATHY) and Oncology (Neo-life). A new division ESSENTIA was also launched to cater to the Hospital sales segment in 2010-11. New products launched were Seretane 2 DT, Rabee 20, Pedimec, Minilactone, Alfalog, Demator, Naprosyn Gel, Lamotrigine dispersible tablets.

The Company sold its Biotech Unit located at Ankleshwar to M/s. Intas Pharmaceuticals Limited as a going concern in 2016-17. It acquired 7 brands from Sun Pharmaceuticals Limited, set up two new divisions viz. Urolife' catering to the urology therapy and Glodiance division catering to the Cosmetic Derma therapy in 2016-17.

In 2017-18, the Company launched brands Darbepoetin (Darba) and Rituximab (XMAB), in the post-transplant care space. Both the brands displayed robust performances in the first year of launch with Darba at third slot among competing Darbepoetin brands. Among the existing products, Immunotac and Arpimune range showed strong growth. In the Africa region, the Company expanded its business with first commercial supply in FY'18. It retained leadership position in Mauritius, through anti-diabetic range while in Egypt, immunosuppressant range remained the best alternative to the innovator brands in the post organ transplant care space.

During 2019, the Company focused on launching new products and driving active promotion in the immunosuppressant range of products and strengthened the oncology portfolio basket by introducing two new monoclonal antibodies. It launched a new product, T-JAKi (JAK Inhibitor) in the immunosuppressant range of products in Rheumatology and Gastroenterology in FY21. As a part of Life Cycle Management strategy of legacy products, Romilast BL and Aldactone T new line extensions were launched. Azoran 75 mg new line extension was launched in 2021. Naprosyn+ and Aldactone-F was launched in FY 2022.

In 2024, the Company launched a digital platform for comprehensive doctor engagement, RPGserv,' which integrates physical and digital capabilities. The Company's portfolio has been strengthened by new launches in Cardiovascular, Diabetology, Nephrology, Rheumatology, Oncology and Urology segments and by entering clinical Dermatology, Orthopedic and Critical Care segments in FY24-25.

Parent organization Goenka R P
NSE symbol RPGLIFE
Founded 2007
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
H V Goenka Chairman (Non-Executive)
Rajesh Shirambekar Company Sec. & Compli. Officer
Sachin Nandgaonkar Independent Director
Zahabiya Khorakiwala Independent Director
Bhaskar Vemban Iyer Independent Director
Rajat Bhargava Non Executive Director
Hiten Kotak Independent Director
Anil Matai Independent Director
Radhika Gupta Independent Director
M K Maheshwari Non Executive Director
Yugal Sikri Non Executive Director
Ashok Nair Managing Director
Vasundhara Patni Non Executive Director
Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
-2.46%
1844.6 -46.70
down-arrow
similar-logo DIVISLAB
0.42%
6887 29.00
down-arrow
similar-logo TORNTPHARM
0.62%
4497 27.79
down-arrow
similar-logo CIPLA
-0.19%
1399.2 -2.70
down-arrow
similar-logo DRREDDY
-0.85%
1307.2 -11.30
down-arrow
similar-logo ZYDUSLIFE
0.24%
1038.95 2.50
down-arrow
similar-logo LUPIN
-0.11%
2281.8 -2.69
down-arrow
similar-logo MANKIND
-1.38%
2479.4 -34.70
down-arrow
similar-logo AUROPHARMA
-5.37%
1463.5 -83.19
down-arrow
similar-logo LAURUSLABS
-0.55%
1343.5 -7.50
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of RPG Life Sciences Ltd?

Answer Field

RPG Life Sciences Ltd share price is for NSE ₹ 2,298.30 & for BSE ₹ 2,299.00 as on May 22 2026 03:29 PM.

What is the Market Cap of RPG Life Sciences Ltd Share?

Answer Field

The market cap of RPG Life Sciences Ltd for NSE ₹ 3,793.90 & for BSE ₹ 0.00 as on May 22 2026 03:29 PM.

What is the 52 Week High and Low of RPG Life Sciences Ltd?

Answer Field

The 52 Week High and Low of RPG Life Sciences Ltd for NSE is ₹ 2,725.00 and ₹ 1,733.00 and for BSE is ₹ 2,715.90 and ₹ 1,731.25.

What is 1 year return for RPG Life Sciences Ltd?

Answer Field

The 1 year returns on the stock has been 4.75%.

What is the P/E Ratio of RPG Life Sciences Ltd Share?

Answer Field

As on May 22 2026 03:29 PM the price-to-earnings (PE) ratio for RPG Life Sciences Ltd share is 32.62.

What is the PB ratio of RPG Life Sciences Ltd Share?

Answer Field

As on May 22 2026 03:29 PM, the price-to-book (PB) ratio for RPG Life Sciences Ltd share is 366.02.

How to Buy RPG Life Sciences Ltd Share?

Answer Field

You can trade in RPG Life Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy RPG Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy RPG Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “RPG Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Products

arrow

Calculators

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email for any investor grievances or write to us for DP related matters.

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email | Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.